[Determination and comparison of pulmonary function with anthropometric indexes in asthmatic and non-asthmatic obese teenagers]

Rev Alerg Mex. 2008 May-Jun;55(3):92-102.
[Article in Spanish]

Abstract

Background: Anomalies in pulmonary function tests in obese are oriented predominantly to restrictive pathology, not been demonstrated efficiently.

Objective: To determine and compare pulmonary function tests (PFT) with anthropometric measurements by spirometry and plethysmograph in asthmatic obese (AO) and non-asthmatic obese (NAO) adolescents.

Patients and method: Cross-sectional study, with 86 adolescents. Obesity was defined as body mass index (BMI) greater to 95% percentile according to CDC and asthma, on the basis of the definition and criteria of GINA guidelines. Clinical history was made, doing anthropometric measures and PFT with determination of: forced vital capacity with maximal expiratory effort, forced expiratory volume in the first second, specific resistance and conductance.

Results: The average age was 12.68 years +/- 1.85, 39 were NAO and 47 AO, who had intermittent to persistent asthma, 14 patients received 200 mcg budesonide/day at least 4 weeks previous to the study. The average values in AO and their standard error for anthropometry were: weight: 68.5 +/- 13.6 kg, height: 154.58 +/- 9.1 cm, BMI: 28.27 +/- 3.24 kg/m2, abdominal circumference (AC): 98 +/- 8.85 cm and hip circumference (HC): 100 +/- 8.87 cm, in NAO: weight: 76.1 +/- 14.7 kg, height: 155.7 +/- 7.85 cm, BMI: 31.04 +/- 4.46 kg/m2, AC: 102 +/- 11.05 cm and HC: 103.28 +/- 10.6 cm.

Conclusions: In NAO post-beta2 Raw diminished whereas Sgaw increased. Greater BMI in AO displayed greater FEV1 with statistic significance. Obstructive ventilator pattern mechanics was observed in both groups.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Adolescent
  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Agonists / therapeutic use
  • Airway Resistance*
  • Anthropometry*
  • Anti-Asthmatic Agents / pharmacology
  • Anti-Asthmatic Agents / therapeutic use
  • Asthma / complications
  • Asthma / drug therapy
  • Asthma / epidemiology
  • Asthma / physiopathology*
  • Body Height
  • Body Mass Index
  • Body Weight
  • Budesonide / therapeutic use
  • Child
  • Cross-Sectional Studies
  • Female
  • Forced Expiratory Volume*
  • Humans
  • Male
  • Mexico / epidemiology
  • Obesity / complications
  • Obesity / epidemiology
  • Obesity / physiopathology*
  • Urban Population / statistics & numerical data
  • Vital Capacity*
  • Waist Circumference
  • Waist-Hip Ratio

Substances

  • Adrenergic beta-Agonists
  • Anti-Asthmatic Agents
  • Budesonide